Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  S-3
Filing Date:  6/25/2012 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 600
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.65  
Change: 
0.05 (1.92%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$397.53M
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. We are primarily focused on commercializing PIXUVRI�(pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe.
Register for a Free Trial and access this filing in:     
  FORM S-3
    CALCULATION OF REGISTRATION FEE
    SUBJECT TO COMPLETION, DATED JUNE 25, 2012
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS
    WHERE YOU CAN FIND MORE INFORMATION
      INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    RISK FACTORS
    USE OF PROCEEDS
    DESCRIPTION OF CAPITAL STOCK
    General Description of Preferred Stock
    Transfer Agent and Registrar
    SELLING SHAREHOLDERS
      BENEFICIAL OWNERS
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    EXPERTS
    PART II
      Item 14. Other Expenses of Issuance and Distribution
      Item 15. Indemnification of Directors and Officers
      Item 16. Exhibits and Financial Statement Schedules
      Item 17. Undertakings
    SIGNATURES
    POWER OF ATTORNEY
    EXHIBIT INDEX
  EXHIBIT 5.1
  EXHIBIT 23.1
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT
  EXHIBIT 23.2
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT